A roundup of mergers & acquisitions news from Sanofi and Kaléo.

Sanofi has agreed to acquire Origimm Biotechnology, a Wien, Austria-based biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease.

The transaction will add ORI-001, a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, to Sanofi’s early-stage pipeline. ORI-001 entered preliminary clinical studies in the third quarter of 2021. In parallel, Sanofi is working to develop additional antigen versions and expects to use its mRNA platform in a Phase I/II trial to start in 2023.  

The acquisition is expected to close in early December 2021.

Source: Sanofi

---

Bio/Pharma Company Kaléo Acquired by Investment Group
Kaléo, a privately held pharmaceutical company headquartered in Richmond, Virginia, has been acquired by the investment group, Marathon Asset Management, for $310 million.

Kaléo is known for the development and commercialization of the Auvi-Q (epinephrine injection, USP) 0.15 mg and 0.3 mg, as well as Auvi-Q (epinephrine injection, USP) 0.1 mg, an epinephrine auto-injector designed for infants and toddlers.

The total base purchase price is approximately $310 million, and includes potential net revenue-based milestone payments of up to approximately $70 million in cash for the 2022 and 2023 fiscal years.

Source: Marathon Asset Management